BAYRY Stock Recent News

Bayer won a big legal victory in its fight to limit liability from claims its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a lawsuit by a Pennsylvania landscaper.

Bayer AG saw its shares soar by 10% in early German trading following a crucial legal victory concerning its Roundup weedkiller. The surge came after a Philadelphia appeals court ruled in favor of Bayer's Monsanto unit, overturning a previous decision that had found the company liable for cancer risks associated with the herbicide.

Bayer AG shares surged up to 12% Friday on news it had won a key victory in a U.S. court that should limit its liability in relation to a series of lawsuits over claims that the popular weed killer Roundup causes cancer.

Bayer shares rose as the company said it scored a legal victory in its suit over claims that exposure to its popular Roundup weed killer led to cancer.

Bayer won a legal victory in its fight to limit liability from claims that its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a lawsuit by a Pennsylvania landscaper.

Bayer reported second quarter results and while the results were nothing to get excited about, it was at least not a disappointment. While the Crop Sciences segment is still struggling, Pharmaceuticals and Consumer Health are growing at a solid pace (at least FX adjusted). While the major risks for the business – high debt levels and litigations – remain, the transformation towards a leaner business structure as well as growth and innovation also takes place.

I recommend keeping a close eye on Bayer's performance and potential investment opportunities. I have been cautious about Bayer since last article, which discussed the company cutting its dividend. Bayer's stock has since rebounded, with potential for further growth due to positive developments in its pharmaceutical and agricultural divisions.

Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.

Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs.

An Australian judge said on Thursday it was not proven that an ingredient in Bayer's Roundup weedkiller increases the risk of cancer in users.